Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 51 of the 54 references it cites were found in a registry or an index; 21 of the 28 sources its claims cite were checked for support.

Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C -mutant Colorectal Cancer

Open access

Published version of a preprint

Abstract

Novel covalent inhibitors of KRASG12C have shown limited response rates in patients with KRASG12C-mutant (MT) colorectal cancer. Thus, novel KRASG12C inhibitor combination strategies that can achieve deep and durable responses are needed. Small-molecule KRASG12C inhibitors AZ’1569 and AZ’8037 were used. To identify novel candidate combination strategies for AZ’1569, we performed RNA sequencing, siRNA, and high-throughput drug screening. Top hits were validated in a panel of KRASG12CMT colorectal cancer cells and in vivo. AZ’1569-resistant colorectal cancer cells were generated and characterized. We found that response to AZ’1569 was heterogeneous across the KRASG12CMT models. AZ’1569 was ineffective at inducing apoptosis when used as a single agent or combined with chemotherapy or agents targeting the EGFR/KRAS/AKT axis. Using a systems biology approach, we identified the antiapoptotic BH3-family member BCL2L1/Bcl-xL as a top hit mediating resistance to AZ’1569. Further analyses identified acute increases in the proapoptotic protein BIM following AZ’1569 treatment. ABT-263 (navitoclax), a pharmacologic Bcl-2 family inhibitor that blocks the ability of Bcl-xL to bind and inhibit BIM, led to dramatic and universal apoptosis when combined with AZ’1569. Furthermore, this combination also resulted in dramatically attenuated tumor growth in KRASG12CMT xenografts. Finally, AZ’1569-resistant cells showed amplification of KRASG12C, EphA2/c-MET activation, increased proinflammatory chemokine profile and cross-resistance to several targeted agents. Importantly, KRAS amplification and AZ’1569 resistance were reversible upon drug withdrawal, arguing strongly for the use of drug holidays in the case of KRAS amplification. Taken together, combinatorial targeting of Bcl-xL and KRASG12C is highly effective, suggesting a novel therapeutic strategy for patients with KRASG12CMT colorectal cancer.

Overview

CoChat Summary

TL;DR

In KRASG12C-mutant colorectal cancer, KRASG12C inhibition alone poorly induces apoptosis, but Bcl-xL blockade releases BIM and produces robust apoptosis when combined with KRASG12C inhibition. Acquired AZ’1569 resistance in this model is driven by KRAS amplification, bypass RTK activation, and a proinflammatory phenotype, and is reversible after drug withdrawal.

Key findings

  • AZ’1569 response was heterogeneous across 7 KRASG12C-mutant colorectal cancer cell lines: IC50 values were 0.26 and 0.43 μmol/L in RW7213 and C106, 1.39, 1.54, and 1.72 μmol/L in SW1463, SW837, and LIM2099, and 2.96 and 3.4 μmol/L in SNU1411 and V481; only RW7213 and C106 showed marked apoptosis after AZ’1569.
  • A 42-target siRNA screen identified BCL2L1/Bcl-xL as the only significant hit sensitizing both SW837 and SNU1411 cells to AZ’1569; Bcl-xL/BAK ratio correlated with AZ’1569 response (r = 0.54), and AZ’1569 acutely increased BIM, which navitoclax/ABT-263 disrupted from Bcl-xL complexes.
  • ABT-737 combined with AZ’1569 was synergistic and induced apoptosis across the KRASG12C-mutant panel; in vivo, navitoclax plus AZ’8037 caused marked tumor shrinkage in SW1463 xenografts and further growth reduction without regression in SNU1411 xenografts.
  • Three AZ’1569-resistant RW7213 clones showed KRAS amplification, elevated KRAS-GTP/mRNA and pERK1/2, c-MET/EphA2 activation, cross-resistance to sotorasib, adagrasib, chemotherapy, and several targeted agents; resistance reversed after 8 weeks of AZ’1569 withdrawal, and resistant clones showed >300-fold increased CD274/PD-L1 and increased IL8, CXCL1, IFNγ, and TGFα.

Methods

  • In vitro studies used 7 KRASG12C-mutant colorectal cancer cell lines plus HCT116, with Sanger sequencing, cell viability assays, caspase-3/7 assays, Western blotting, immunoprecipitation, RT-PCR, cytokine/RTK arrays, ELISAs, RAS-GTP assays, RNA-seq, a 42-target siRNA screen, and a 45-compound drug screen.
  • In vivo efficacy used NOD SCID mice bearing SNU1411 or SW1463 xenografts; mice received vehicle, AZ’8037 (100 mg/kg orally daily), navitoclax (100 mg/kg orally 5 of 6 days), or the combination, with eight animals per group.
  • Analyses included robust z-scores, Chou-Talalay combination index/RI values, GraphPad statistics, and MedExome/NGS for resistant clones.

Limitations

  • Stated in the paper: further biomarker analysis of patient tissue is needed to confirm the predictive role of BIM; the navitoclax/AZ’8037 combination was less well tolerated in the SNU1411 model; and SNU1411 xenografts showed no tumor regression with the combination.
  • Evident from the text: the main findings are preclinical, based on a small panel of 7 KRASG12C-mutant colorectal cancer cell lines and two xenograft models, with acquired resistance generated from a single sensitive cell line (RW7213) and three resistant clones.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-22-0301

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1. Response to AZ’1569 in KRASG12C MT colorectal cancer cells. A,KRASG12CMT colorectal cancer cells were treated with increasing concentrations of AZ’1569 for 120 hours and cell viability determined using CTG assay. IC50 values were calculated using Prism software package. Dashed line indicates 50% cell viability. Representative of three independent experiments is shown. B, Colorectal cancer cells were treated with AZ’1569 for 48 hours. PARP, cleaved C3, and KRAS were determined by WB (top), caspase-3/7 activity levels were measured with values presented as a percentage of their respective controls. Significance was analyzed using an unpaired t test (bottom). (Cl = cleaved). C, Signaling analysis upon AZ’1569 treatment. KRASG12C MT colorectal cancer cell lines were treated with 1 μmol/L AZ’1569 for the indicated times, and protein lysates were used for WB analysis for the KRAS downstream effectors. Densitometry on WB images was quantified using ImageJ software and normalized to the respective untreated control. Dashed lines on the graphs represent a value of 1.
Figure 1. Response to AZ’1569 in KRASG12C MT colorectal cancer cells. A,KRASG12CMT colorectal cancer cells were treated with increasing concentrations of AZ’1569 for 120 hours and cell viability determined using CTG assay. IC50 values were calculated using Prism software package. Dashed line indicates 50% cell viability. Representative of three independent experiments is shown. B, Colorectal cancer cells were treated with AZ’1569 for 48 hours. PARP, cleaved C3, and KRAS were determined by WB (top), caspase-3/7 activity levels were measured with values presented as a percentage of their respective controls. Significance was analyzed using an unpaired t test (bottom). (Cl = cleaved). C, Signaling analysis upon AZ’1569 treatment. KRASG12C MT colorectal cancer cell lines were treated with 1 μmol/L AZ’1569 for the indicated times, and protein lysates were used for WB analysis for the KRAS downstream effectors. Densitometry on WB images was quantified using ImageJ software and normalized to the respective untreated control. Dashed lines on the graphs represent a value of 1.CC BY · PubMed Central
Figure 2. AZ’1569 combined with chemotherapy or cetuximab does not induce apoptosis in KRASG12C MT colorectal cancer cells. A, CTG assays in colorectal cancer cells treated with no drug (control), 5-FU, AZ’1569, or 5-FU in combination with AZ’1569 for 72 hours. CI values were calculated using the method of Chou and Talalay. CI values <1, >1, and equal to 1 indicate synergy, antagonism, and additive effects for the drug combinations, respectively. Dashed lines indicate CI values of 0.3, 0.7, and 1. Representative results of at least three experiments (left). Absolute cell viability for different combinations (right). Dashed line indicates 50% cell viability. B, Colorectal cancer cells were cotreated with AZ’1569 and 5-FU, oxaliplatin, or SN-38 for 48 hours. Top: PARP, caspase 9, caspase 3, caspase 8, and KRAS levels were determined by WB. Bottom: Apoptosis was assessed by caspase 3/7 activity assay. * = nonspecific band. C, CTG cell viability assays in KRASG12C MT colorectal cancer cells cotreated with AZ’1569 and cetuximab for 120 hours. CI values were calculated to evaluate the nature of interaction. D,KRASG12C MT colorectal cancer cells were cotreated with AZ’1569 and cetuximab for 48 hours, apoptosis was assessed by WB analysis for PARP (top) and caspase-3/7 activity assays (bottom). A two-way ANOVA was used to analyze statistical significance.
Figure 2. AZ’1569 combined with chemotherapy or cetuximab does not induce apoptosis in KRASG12C MT colorectal cancer cells. A, CTG assays in colorectal cancer cells treated with no drug (control), 5-FU, AZ’1569, or 5-FU in combination with AZ’1569 for 72 hours. CI values were calculated using the method of Chou and Talalay. CI values <1, >1, and equal to 1 indicate synergy, antagonism, and additive effects for the drug combinations, respectively. Dashed lines indicate CI values of 0.3, 0.7, and 1. Representative results of at least three experiments (left). Absolute cell viability for different combinations (right). Dashed line indicates 50% cell viability. B, Colorectal cancer cells were cotreated with AZ’1569 and 5-FU, oxaliplatin, or SN-38 for 48 hours. Top: PARP, caspase 9, caspase 3, caspase 8, and KRAS levels were determined by WB. Bottom: Apoptosis was assessed by caspase 3/7 activity assay. * = nonspecific band. C, CTG cell viability assays in KRASG12C MT colorectal cancer cells cotreated with AZ’1569 and cetuximab for 120 hours. CI values were calculated to evaluate the nature of interaction. D,KRASG12C MT colorectal cancer cells were cotreated with AZ’1569 and cetuximab for 48 hours, apoptosis was assessed by WB analysis for PARP (top) and caspase-3/7 activity assays (bottom). A two-way ANOVA was used to analyze statistical significance.CC BY · PubMed Central
Figure 3. Bcl-xL regulates intrinsic resistance to KRASG12C inhibition in KRASG12C MT colorectal cancer. A, Targeted siRNA screen in SW837 and SNU1411 cells. Top: SW837 and SNU1411 cells were reverse transfected with 10 nmol/L ON-Targetplus siRNA's targeting 42 genes in the absence or presence of 1 μmol/L AZ’1569 for 72 hours and cell viability was evaluated using the CTG assay. Scatter plot showing rZ for siRNA screen in SW837 and SNU1411 cells. Positive scores indicate potential mediators of sensitivity to AZ’1569, while negative scores indicate mediators of resistance to AZ’1569. Dashed lines indicate rZ = 0, 1.5, and −1.5; cut-off thresholds of ±1.5 were applied to the data. Bottom: The siRNA approach and analysis. XY graph illustrates hits resulting in sensitization or resistance to AZ’1569 in both cell lines. Data show average rZ-scores from three independent experiments. B, Colorectal cancer cells were transfected with 10 nmol/L on-target SMARTpool siRNA against BCL2L1 and cotreated with 1 μmol/L AZ’1569 (0.25 μmol/L AZ’1569 for RW7213 and C106 cells) for 24 hours (48 hours for SNU1411) and apoptosis assessed by WB for PARP and cleaved caspase 8 and 3 (top) and caspase 3/7 activity assay (bottom). n.d denotes not detected. A two-way ANOVA was used to evaluate significance. C, Expression of PARP, cleaved caspase 9, caspase 8, Myc-tag, and KRAS in SW837 and RW7213 cells transiently transfected with 1 μg of Myc-tagged Bcl-xL for 24 hours, followed by treatment with 1 μmol/L AZ’1569 (AZD) for the indicated times. Caspase-3/7 activity on cell lysates was also determined. A two-way ANOVA was used to evaluate significance.
Figure 3. Bcl-xL regulates intrinsic resistance to KRASG12C inhibition in KRASG12C MT colorectal cancer. A, Targeted siRNA screen in SW837 and SNU1411 cells. Top: SW837 and SNU1411 cells were reverse transfected with 10 nmol/L ON-Targetplus siRNA's targeting 42 genes in the absence or presence of 1 μmol/L AZ’1569 for 72 hours and cell viability was evaluated using the CTG assay. Scatter plot showing rZ for siRNA screen in SW837 and SNU1411 cells. Positive scores indicate potential mediators of sensitivity to AZ’1569, while negative scores indicate mediators of resistance to AZ’1569. Dashed lines indicate rZ = 0, 1.5, and −1.5; cut-off thresholds of ±1.5 were applied to the data. Bottom: The siRNA approach and analysis. XY graph illustrates hits resulting in sensitization or resistance to AZ’1569 in both cell lines. Data show average rZ-scores from three independent experiments. B, Colorectal cancer cells were transfected with 10 nmol/L on-target SMARTpool siRNA against BCL2L1 and cotreated with 1 μmol/L AZ’1569 (0.25 μmol/L AZ’1569 for RW7213 and C106 cells) for 24 hours (48 hours for SNU1411) and apoptosis assessed by WB for PARP and cleaved caspase 8 and 3 (top) and caspase 3/7 activity assay (bottom). n.d denotes not detected. A two-way ANOVA was used to evaluate significance. C, Expression of PARP, cleaved caspase 9, caspase 8, Myc-tag, and KRAS in SW837 and RW7213 cells transiently transfected with 1 μg of Myc-tagged Bcl-xL for 24 hours, followed by treatment with 1 μmol/L AZ’1569 (AZD) for the indicated times. Caspase-3/7 activity on cell lysates was also determined. A two-way ANOVA was used to evaluate significance.CC BY · PubMed Central
Figure 4. High-throughput drug screen reveals that pharmacologic inhibition of Bcl-xL synergizes with KRASG12C inhibition in KRASG12C MT colorectal cancer. A, SW837 and SNU1411 cells were cotreated with 1 μmol/L AZ’1569 alone or combined with a panel of 45 small-molecule inhibitors for 72 hours and cell viability assessed using the CTG assay. Three concentrations per drug were tested (Supplementary Table S2). Cell viability was analyzed using a CTG assay. Scatter plot showing rZ for each compound concentration used in the drug screen. Negative rZ-scores indicate agents that sensitize to AZ’1569, and vice versa. Dashed lines on graphs indicate values of 1.5 and −1.5. Venn diagram indicates number of compounds (past a threshold of rZ = −1.5) that resulted in sensitization to AZ’1569 in both cell lines. B, CTG cell viability assays in KRASG12C MT colorectal cancer cells cotreated with AZ’1569 and ABT-737 for 72 hours. CI values were calculated to evaluate the nature of interaction. Absolute cell viability for AZ’1569/ABT-737 combinations in SW847 and SNU1411 cell lines are also shown. Dashed lines on graphs represent 50% cell viability. C, PARP, cleaved C9, cleaved C8, cleaved C3, and KRAS expression levels in KRASG12C MT colorectal cancer cells cotreated with AZ’1569 and ABT-737 for 48 hours (24 hours for RW7213, SW1463, and V481 cells). CM = combination. D,KRASG12C MT colorectal cancer cells were treated with AZ’1569 alone or combined with cetuximab or ABT-737 (0.25 μmol/L for C106, LIM2099, SNU1411; 0.5 μmol/L for SW837, V481, RW7213 and 2.5 μmol/L for SW1463) for 48 hours (24 hours for C106 cells) and PARP, cleaved C9, cleaved C8, and cleaved C3 determined by WB.
Figure 4. High-throughput drug screen reveals that pharmacologic inhibition of Bcl-xL synergizes with KRASG12C inhibition in KRASG12C MT colorectal cancer. A, SW837 and SNU1411 cells were cotreated with 1 μmol/L AZ’1569 alone or combined with a panel of 45 small-molecule inhibitors for 72 hours and cell viability assessed using the CTG assay. Three concentrations per drug were tested (Supplementary Table S2). Cell viability was analyzed using a CTG assay. Scatter plot showing rZ for each compound concentration used in the drug screen. Negative rZ-scores indicate agents that sensitize to AZ’1569, and vice versa. Dashed lines on graphs indicate values of 1.5 and −1.5. Venn diagram indicates number of compounds (past a threshold of rZ = −1.5) that resulted in sensitization to AZ’1569 in both cell lines. B, CTG cell viability assays in KRASG12C MT colorectal cancer cells cotreated with AZ’1569 and ABT-737 for 72 hours. CI values were calculated to evaluate the nature of interaction. Absolute cell viability for AZ’1569/ABT-737 combinations in SW847 and SNU1411 cell lines are also shown. Dashed lines on graphs represent 50% cell viability. C, PARP, cleaved C9, cleaved C8, cleaved C3, and KRAS expression levels in KRASG12C MT colorectal cancer cells cotreated with AZ’1569 and ABT-737 for 48 hours (24 hours for RW7213, SW1463, and V481 cells). CM = combination. D,KRASG12C MT colorectal cancer cells were treated with AZ’1569 alone or combined with cetuximab or ABT-737 (0.25 μmol/L for C106, LIM2099, SNU1411; 0.5 μmol/L for SW837, V481, RW7213 and 2.5 μmol/L for SW1463) for 48 hours (24 hours for C106 cells) and PARP, cleaved C9, cleaved C8, and cleaved C3 determined by WB.CC BY · PubMed Central
Figure 5. Combined KRASG12C and Bcl-xL inhibition results in reduction in growth of KRASG12C MT colorectal cancer in vivo. A, Growth rate (left) and mouse weight (right) of SW1463 xenografts in NOD/SCID mice treated with vehicle, AZ’8037, navitoclax, or AZ’8037 in combination with navitoclax. Differences in growth were determined using a one-way ANOVA with Tukey test for multiple comparisons. WB analysis for pERK1/2, ERK1/2, and KRAS in tumor samples collected at day 15. B, Growth rate (left) and mouse weight (right) of SNU1411 xenografts in NOD/SCID mice treated with vehicle, AZ’8037, navitoclax, or AZ’8037 in combination with navitoclax.
Figure 5. Combined KRASG12C and Bcl-xL inhibition results in reduction in growth of KRASG12C MT colorectal cancer in vivo. A, Growth rate (left) and mouse weight (right) of SW1463 xenografts in NOD/SCID mice treated with vehicle, AZ’8037, navitoclax, or AZ’8037 in combination with navitoclax. Differences in growth were determined using a one-way ANOVA with Tukey test for multiple comparisons. WB analysis for pERK1/2, ERK1/2, and KRAS in tumor samples collected at day 15. B, Growth rate (left) and mouse weight (right) of SNU1411 xenografts in NOD/SCID mice treated with vehicle, AZ’8037, navitoclax, or AZ’8037 in combination with navitoclax.CC BY · PubMed Central
Figure 6. AZ’1569-acquired resistant cells exhibit increased PD-L1 expression and a proinflammatory phenotype. A, Left: RW7213 parental and AZ’1569-resistant clones (No. 2, No. 3, and No. 4) were treated for 72 hours with indicated concentrations of AZ’1569 or sotorasib, and cell viability was determined using CTG assays. Right: Lysates from RW7213 parental and AZ’1569-resistant clones were analyzed by WB for KRAS, pEGFRY1068, EGFR, pMETY1234/1235, MET, pERK1/2T202/Y204, ERK1/2, pS6S235/6, S6, pAKTS473, AKT, pEphA2S897, pEphA2Y588, pEphA2Y772, and EphA2. Active Raf1-bound Ras was isolated from RW7213 parental and resistant clones using an RAS-GTP assay and basal GTP-bound and total KRAS levels assessed by WB. LE = longer exposure. KRAS mRNA was quantified using RT-PCR. Raw values were normalized to ACTB and GAPDH expression and were analyzed using the ΔΔCT method. A one-way ANOVA was used to calculate statistical significance. Data are representative of three independent experimental repeats. Results of NGS of RW7213 Par and AZ’1569-R clones are shown. B, RW7213 parental and resistant cells were treated with SHP-099, BI-3406, 5-FU, SN-38, oxaliplatin, crizotinib, cetuximab, dasatinib, trametinib, ulixertinib, capivasertib, PF-4708671, AZD1480, ONC206, ABT-737, sabutoclax or entinostat for 72 hours, at the indicated concentrations and cell viability was assessed using CTG assays. Heatmap represents cell viability relative to control. Data are representative of three independent experimental repeats. C, Top left: Human cytokine array using conditioned medium of RW7213 parental and resistant clones. Right: Mean spot pixel density was analyzed using Image J, rZ (relative to parental cells) were calculated using densitometry data and presented in a heatmap. Bottom left: CXCL1, CD274, and IL8 mRNA in parental and resistant clones were quantified using RT-PCR. Raw values were normalized to the expression of housekeeping genes ACTB and GAPDH and were analyzed using the ΔΔCT method. CXCL1 protein levels in the culture media of parental (Par) and resistant subpopulations were measured by ELISA. A one-way ANOVA was used to calculate statistical significance. Data are representative of three independent experimental repeats. D, Left: Dose–response curves for AZ’1569 in RW7213 cells, incubated with conditioned media from parental cells or drug-resistant clones No. 2, No. 3, or No. 4. Cells were treated for 72 hours and cell viability was determined using CTG assay. IC50 values were calculated using a Prism software package. Dashed line indicates 50% cell viability. A representative of three independent experiments is shown. Right: A 24-well 5-μm polycarbonate Transwell insert-plate system was used. 2.5 × 105 PBMCs were resuspended in 2% FCS-supplemented DMEM and were added to the top chamber. The bottom chamber was filled with conditioned medium (medium = 2% FCS-supplemented DMEM) obtained from RW7213 parental and resistant cells. Cells were incubated for 4 hours, following which CellTiter-Glo was used to measure PBMC migration to the bottom chamber (RLU = relative luminescence). Serum-free DMEM was used in the bottom chamber as a negative control (neg CT). Data are representative of three independent experimental repeats.
Figure 6. AZ’1569-acquired resistant cells exhibit increased PD-L1 expression and a proinflammatory phenotype. A, Left: RW7213 parental and AZ’1569-resistant clones (No. 2, No. 3, and No. 4) were treated for 72 hours with indicated concentrations of AZ’1569 or sotorasib, and cell viability was determined using CTG assays. Right: Lysates from RW7213 parental and AZ’1569-resistant clones were analyzed by WB for KRAS, pEGFRY1068, EGFR, pMETY1234/1235, MET, pERK1/2T202/Y204, ERK1/2, pS6S235/6, S6, pAKTS473, AKT, pEphA2S897, pEphA2Y588, pEphA2Y772, and EphA2. Active Raf1-bound Ras was isolated from RW7213 parental and resistant clones using an RAS-GTP assay and basal GTP-bound and total KRAS levels assessed by WB. LE = longer exposure. KRAS mRNA was quantified using RT-PCR. Raw values were normalized to ACTB and GAPDH expression and were analyzed using the ΔΔCT method. A one-way ANOVA was used to calculate statistical significance. Data are representative of three independent experimental repeats. Results of NGS of RW7213 Par and AZ’1569-R clones are shown. B, RW7213 parental and resistant cells were treated with SHP-099, BI-3406, 5-FU, SN-38, oxaliplatin, crizotinib, cetuximab, dasatinib, trametinib, ulixertinib, capivasertib, PF-4708671, AZD1480, ONC206, ABT-737, sabutoclax or entinostat for 72 hours, at the indicated concentrations and cell viability was assessed using CTG assays. Heatmap represents cell viability relative to control. Data are representative of three independent experimental repeats. C, Top left: Human cytokine array using conditioned medium of RW7213 parental and resistant clones. Right: Mean spot pixel density was analyzed using Image J, rZ (relative to parental cells) were calculated using densitometry data and presented in a heatmap. Bottom left: CXCL1, CD274, and IL8 mRNA in parental and resistant clones were quantified using RT-PCR. Raw values were normalized to the expression of housekeeping genes ACTB and GAPDH and were analyzed using the ΔΔCT method. CXCL1 protein levels in the culture media of parental (Par) and resistant subpopulations were measured by ELISA. A one-way ANOVA was used to calculate statistical significance. Data are representative of three independent experimental repeats. D, Left: Dose–response curves for AZ’1569 in RW7213 cells, incubated with conditioned media from parental cells or drug-resistant clones No. 2, No. 3, or No. 4. Cells were treated for 72 hours and cell viability was determined using CTG assay. IC50 values were calculated using a Prism software package. Dashed line indicates 50% cell viability. A representative of three independent experiments is shown. Right: A 24-well 5-μm polycarbonate Transwell insert-plate system was used. 2.5 × 105 PBMCs were resuspended in 2% FCS-supplemented DMEM and were added to the top chamber. The bottom chamber was filled with conditioned medium (medium = 2% FCS-supplemented DMEM) obtained from RW7213 parental and resistant cells. Cells were incubated for 4 hours, following which CellTiter-Glo was used to measure PBMC migration to the bottom chamber (RLU = relative luminescence). Serum-free DMEM was used in the bottom chamber as a negative control (neg CT). Data are representative of three independent experimental repeats.CC BY · PubMed Central

Verification

Claims the paper makes

14 Valid · 2 Not valid · 4 Not checked · 105 Own results and interpretations

86 more claims · 4 with their cited sources checked

Create a free account to see all 125 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 10
  • It may state two separate claims as one. 25

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

4 of 4

Citations

Cites

Show all 54 references

Cited by

See all 12

Metadata

Authors
Khawaja, H., Briggs, R., Latimer, C. H., Rassel, M., Griffin, D., Hanson, L., Bardelli, A., Di Nicolantonio, F., McDade, S. S., Scott, C. J., Lambe, S., Maurya, M., Lindner, A. U., Prehn, J. H. M., Sousa, J., Winnington, C., LaBonte, M. J., Ross, S., & Van Schaeybroeck, S.
Affiliations
  • Queen's University Belfast (GB)
  • AstraZeneca (United Kingdom) (GB)
  • Candiolo Cancer Institute (IT)
  • 3Department of Oncology, University of Torino, Candiolo, Torino, Italy.
  • Royal College of Surgeons in Ireland (IE)
  • 1Drug Resistance Group, Patrick G. Johnston Centre for Cancer Research, School of Medicine, Dentistry and Biomedical Science, Queen's University Belfast, Belfast, United Kingdom.
Venue
Molecular Cancer Therapeutics
Published
2022-10-22
Volume
22
Issue
1
Pages
135-149
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W4307187376
Cited by
12
References
54
Citations by year
2026: 4 · 2025: 3 · 2024: 2 · 2023: 3
FWCI
0.65
Type
journal article
Language
en
Open access
Locations
  • Molecular Cancer Therapeutics (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research Portal (Queen's University Belfast) (publishedVersion, cc-by)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
  • Figshare (submittedVersion, cc-by)
  • Lenus, The Irish Health Repository (Dr Steevens Hospital Library) (submittedVersion)
Funders
  • Cancer Research UK (C212/A7402)
  • European Commission (602901)
  • Science Foundation Ireland (16/US/3301)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Keywords
KRAS G12C, colorectal cancer, Bcl-xL, apoptosis, building information modeling, navitoclax, drug resistance, KRAS amplification, EphA2, c-Met, drug holidays, combination therapy
MeSH terms
Antineoplastic Agents, Humans, Proto-Oncogene Proteins, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Apoptosis, Proto-Oncogene Proteins c-bcl-2, Cell Line, Tumor, bcl-X Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C -mutant Colorectal Cancer. https://app.cochat.ai/papers/10.1158/1535-7163.mct-22-0301
The paper
Khawaja, H., Briggs, R., Latimer, C. H., Rassel, M., Griffin, D., Hanson, L., Bardelli, A., Di Nicolantonio, F., McDade, S. S., Scott, C. J., Lambe, S., Maurya, M., Lindner, A. U., Prehn, J. H. M., Sousa, J., Winnington, C., LaBonte, M. J., Ross, S., & Van Schaeybroeck, S. (2023). Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C -mutant Colorectal Cancer. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-22-0301

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.